Dr. Guangying Zhu
EDUCATION AND TRAINING
1997-2000:
Doctor of Philosophy. Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Major: Radiation Oncology.
Supervisor: Prof. Weiming Cai.
Research Projects:
1.Brain injury caused by irradiation correlative gene expression and its treatment with traditional Chinese medicine.
2.Nested RT-PCR to detect the minor metastasis cells in the peripheral blood of cancer patient
1987-1990:
Master of Medical Science. Faculty of Medicine, Suzhou Medical University, Suzhou, China.
Major: Radiology. Minors: CT diagnosis.
Supervisor: Prof. Minhui Qian
Thesis Topic:
Diagnosis of pancreatic cancer with CT
1979-1984:
Doctor of Medicine. Faculty of Medicine, Xuzhou Medical University, Xuzhou, China.
Fully trained in medical science.
2007.6 National Pharmaceutical Base Training, Certificate No.J13-07-20
EXPERIENCE
2011.4 to present: Director of Department of Radiation Oncology, professor
2005.9-2011.3: Vice director of Department of Radiation Oncology, professor
2004.1-2005.4 Visiting professor of Department of Radiation Oncology, MD Anderson Cancer Center, USA
2001.8-2005.8: Vice director of Department of Radiation Oncology, vice professor
1992-1997: Department of Experimental Radiation Oncology, Xuzhou Medical University
1991-1992: Department of CT Diagnosis, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
1984-1987: Assistant Master and Lecturer, Department of Radiology
TECHNICAL EXPERIENCE
Cancer Radiology and Radiation Oncology
X-ray, CT, MR diagnosis of common cancer
Establishment of mouse model of lung adenocarcinoma
Establishment of animal model of brain damaged by irradiation
Neural cell isolation and culturing
Differential display PCR to seek new gene related with radiation injury or new molecular mark of metastasis
DNA and RNA isolation and purification; PCR amplification; RT-PCR; Southern and Northern blot Hybridizations; Gene transfection
Immunohistochemistry
Tissue culture
Methods of statistical analysis
Speaker of conference:
1. EGFR Mutation Status Predict Survival and Response for Patients with Stage III Squamous-Cell Carcinoma of Lung Treated with Chemoradiotherapy. Oral presentation 2011 ASTRO, Abstr. No. 268
2. A Randomized Controlled Phase II Trial to Compare Efficacy and Toxicities of Two Regimens of Paclitaxel in Concurrent Radiochemotherapy for Patients with Locally Advanced Non-small Cell Lung Cancer. Oral presentation 2010 ASTRO, Abstr. No. 233